Education and learning
Royal College of Physicians and Surgeons of Canada
Dr. Eyal Grunebaum was appointed the Paediatric Clinical Immunology & Allergy Residency Program Director effective September 2011 while Dr. Chaim Roifman continues to be the Paediatric Clinical Immunology and Allergy Fellowship Director.
The goal of this program at The Hospital for Sick Children is to generate sub-specialists in paediatric Immunology and Allergy, who will provide the medical community with expert consultation. This two-year program, affiliated with St. Michael's Hospital and Toronto Western Hospital attracts residents from around the world and exceeds the essential clinical and laboratory elements that permit outstanding immunology and allergy training. The program provides individual training, with flexibility to accommodate resident's interests and career goals by presenting opportunities for focusing on immunology, allergy, academia, or community practice. Clinically, the program offers extensive in-patient and outpatient training via efficiently structured rotations, rounds, and clinics that are embedded with well-organized academic content. There is an extensive exposure to transplantation with a high level of case diversity, with strong links with the adult immunology/allergy training program at St. Michael's Hospital. The important linkages between the bedside and bench, SickKids is committed to the incorporation of research training into the program. The faculty of immunology and allergy at SickKids are committed to guide residents through all aspects of research. A mandatory, lab oriented, basic research project, along with directions on proposal and grant applications, encourage the participation of residents in tangible publications. The accommodating research and clinical staff, an office with personal working space, computer accessibility, and a swiftly reported evaluation provides the fellow residents with an excellent learning environment.
Bayer Complimentary Fellowship in Immunology
This innovative program in partnership with the Canadian Institute of Health Research (CIHR) encourages today's clinicians to train as scientists in the field of immunodeficiency and novel immune therapies. Currently, there is an increase in demand for the number of expert physicians in allergy and clinical immunology. The Bayer Program aids in this endeavor, by heightening the contributions of Canada in the future care and research of clinical immunology and allergy.
Aventis Fellowship in Clinical and Basic Immunology
The Aventis Fellowship in Immunology is a one-year research fellowship, which enhances the exposure of Immunology recruits to applied or basic research, in order to attain the skills needed to pursue an academic career in clinical immunology. Only candidates who have competed two years of basic training in an accredited Royal College of Physicians and Surgeons program in Canada are eligible. With only 20 per cent clinical activities, fellows obtain the necessary time to focus on an immunological based research project of their choice, whereby they will be assisted and trained in a multitude of modern techniques in science, and guided in the preparation, design and implementation of scientific experiments. Thus, the Aventis Fellowship fulfills a critical requirement for a third year of training which focuses on scholar activities, emphasizing the importance of the bench aspect of a clinician-scientist.
The Hospital for Sick Children - Tel Aviv University (SickKids-TAU) Exchange Program Fellowship
With a relatively high prevalence rate of Primary Immunodeficiencies in Israel (approximately five in 100, 000 inhabitants), this alliance between SickKids and TAU is a vital component in the education sector of the International Center for Primary Immunodeficiencies. This union assists in the training of young physicians and scientists in the filed of immune disorders via facilitating the transfer of knowledge and expertise between SickKids and TAU. It correspondingly promotes research collaborations between SickKids and TAU to foster global innovation in immunobiology for the benefit of mankind.
For more information contact Eyal Grunebaum.